Entrada Therapeutics, Inc. TRDA
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and ENTR-601-45 clinical trials, an EU filing for the ENTR-601-50 clinical trial, and regulatory submissions for ENTR-601-51. In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with dosing completion anticipated in mid-2026. We anticipate reporting on the results of two cohorts of patient data from our ENTR-601-44 program, and one from our ENTR-601-45 program during 2026.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — | — | — |
| R&D | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M | $21.1M | — |
| SG&A | $41.0M | $38.5M | $32.3M | $30.6M | $15.2M | $5.6M | — |
| Total operating expenses | $183.3M | $163.8M | $132.2M | $97.2M | $51.1M | $26.7M | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M | -$26.7M | — |
| Pre-tax income | -$142.8M | $66.5M | $12.1M | -$94.6M | -$51.2M | -$26.5M | — |
| Income tax | $924.0K | $859.0K | $18.7M | $0 | $0 | $0 | — |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M | -$26.5M | — |
| EPS, basic | -3.47 | 1.76 | -0.20 | -3.02 | -8.16 | -24.00 | — |
| EPS, diluted | -3.47 | 1.68 | -0.20 | -3.02 | -8.16 | -24.00 | — |
| Shares, diluted (wtd. avg.) | 41.4M | 39.0M | 33.1M | 31.3M | 6.3M | 1.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.4M | $101.2M | $71.6M | $49.1M | $291.1M | $39.0M | $16.8M |
| Total current assets | $306.3M | $440.0M | $369.8M | $209.9M | $298.7M | $39.9M | — |
| Property, plant and equipment | $7.3M | $10.9M | $11.2M | $7.7M | $6.3M | $3.0M | — |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M | $43.5M | — |
| Accounts payable | $2.3M | $4.3M | $3.3M | $6.0M | $706.0K | $1.6M | — |
| Total current liabilities | $24.5M | $39.5M | $158.8M | $22.0M | $6.7M | $3.4M | — |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M | $3.4M | — |
| Retained earnings | -$273.1M | -$129.3M | -$195.0M | -$188.3M | -$93.7M | -$42.5M | — |
| Total equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M | -$41.5M | -$15.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M | -$25.6M | — |
| Depreciation and amortisation | $4.1M | $3.8M | $2.8M | $1.9M | $1.1M | $326.0K | — |
| Stock-based compensation | $19.6M | $17.9M | $13.1M | $9.9M | $2.5M | $325.0K | — |
| Capital expenditure | $1.0M | $3.2M | $5.6M | $2.9M | $4.6M | $2.3M | — |
| Investing cash flow | $116.8M | -$27.8M | -$138.4M | -$148.7M | -$4.6M | -$2.3M | — |
| Financing cash flow | $887.0K | $103.0M | $21.0M | $479.0K | $307.5M | $50.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001689375-26-000011.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $129.0M | $210.8M | $25.4M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |